Exciting Developments in Treating Neurogenic Orthostatic Hypotension
Theravance Biopharma, Inc. (NASDAQ: TBPH) has gathered significant insights regarding its investigational drug, ampreloxetine. These analyses delve deep into the Phase 3 program focused on neurogenic orthostatic hypotension (nOH), a condition that poses significant challenges for patients, especially those with multiple system atrophy (MSA). As this clinical journey unfolds, the company is eager to share its findings during the 77th Annual Meeting of the American Academy of Neurology.
Details of the Presentation
The presentation will be held during a platform session set for April 7, focusing on the impact of ampreloxetine on patients suffering from nOH. One of the notable studies, presented by Iodice V, titled NET-Inhibition with Ampreloxetine, Blood Pressure, and Catecholamines in Patients with Neurogenic Orthostatic Hypotension will shed light on the pharmacologic nuances of this treatment. Another crucial study, led by Norcliffe-Kaufmann L, will explore The Impact of Ampreloxetine on Supine Hypertension: An Ambulatory Blood Pressure Monitoring Study, marking a significant step in understanding this therapy's benefits.
Ampreloxetine's Efficacy
Ampreloxetine is a once-daily norepinephrine reuptake inhibitor that has shown promise in treating symptomatic nOH associated with MSA. Insights gained from Study 0170 affirm its potential, which includes elevating norepinephrine levels and positively influencing blood pressure without exacerbating supine hypertension. The treatment aims to alleviate debilitating symptoms, allowing patients a better quality of life.
Understanding the CYPRESS Study
The ongoing Phase 3 CYPRESS study, designed to assess the efficacy of ampreloxetine amongst MSA sufferers, emphasizes detailed evaluations of its long-term impacts on symptom management. With an enrollment strategy that ensures comprehensive data collection, the study evaluates sleep and daily functioning to meet the critical needs of affected individuals. This includes focused assessments on the Orthostatic Hypotension Symptom Assessment (OHSA) scores, correlating treatment necessaries with tangible health improvements.
Multiple System Atrophy and Its Symptoms
Multiple system atrophy is a progressive disease that disrupts motor function and autonomic control, leading to a significant challenge for patients who experience a drop in blood pressure upon standing—a defining trait of nOH. Current research indicates that about 50,000 people in the U.S. have MSA, with a striking 70-90% experiencing nOH symptoms, demonstrating the urgent need for effective treatments like ampreloxetine.
About Theravance Biopharma
Theravance Biopharma is dedicated to delivering Medicines that Make a Difference® in the lives of those affected by various health challenges. With a robust pipeline, the company looks to develop therapeutics that not only address critical conditions but also enhance the quality of life for patients. The commitment to innovating solutions such as ampreloxetine signifies Theravance's pursuit of excellence in the pharmaceutical landscape.
Frequently Asked Questions
What is ampreloxetine?
Ampreloxetine is an investigational norepinephrine reuptake inhibitor developed to treat neurogenic orthostatic hypotension, particularly in patients with MSA.
When will the findings on ampreloxetine be presented?
The findings will be showcased on April 7 during the 77th Annual Meeting of the American Academy of Neurology.
What is the CYPRESS study?
CYPRESS is a Phase 3 study aimed at evaluating the treatment efficacy of ampreloxetine for patients with symptomatic nOH due to MSA.
What are the symptoms of neurogenic orthostatic hypotension?
Symptoms include dizziness, lightheadedness, fatigue, and fainting, which occur after standing due to sudden drops in blood pressure.
How many patients are affected by MSA?
Approximately 50,000 individuals in the U.S. suffer from multiple system atrophy, with many experiencing debilitating symptoms related to nOH.
